Context Theory and simulation suggest that randomized controlled trials (RCTs) stopped
early for benefit (truncated RCTs) systematically overestimate treatment effects for the …

Background Nitric oxide (NO) is a major endogenous regulator of vascular tone. Inhaled
nitric oxide (iNO) gas has been investigated as treatment for persistent pulmonary …

Inhaled nitric oxide (iNO) acts as a selective pulmonary vasodilator and it is currently
approved by the FDA for the treatment of persistent pulmonary hypertension of the newborn …

Objective. To determine the effect of inhaled nitric oxide (NO) on clinical outcome in
newborns with persistent pulmonary hypertension (PPHN). Design. A prospective …

AIM To determine whether treatment with inhaled nitric oxide (NO) and/or dexamethasone
reduces the incidence of chronic lung disease (CLD) and/or death in high risk preterm …

Inhaled nitric oxide (iNO) was first used in neonatal practice in 1992 and has subsequently
been used extensively in the management of neonates and children with cardiorespiratory …

Pulmonary arterial hypertension (PAH) is a rare disease in infants and children that is
associated with significant morbidity and mortality. The disease is characterized by …

Pediatric pulmonary hypertension (PPH) is a multifactorial disease with diverse etiologies
and presenting features. Pulmonary hypertension (PH), defined as elevated pulmonary …

Inhaled nitric oxide (INO) is a colorless, odorless gas that is also a potent pulmonary
vasodilator. When given via the inhaled route it is a selective pulmonary vasodilator. INO is …

Background: Inhaled nitric oxide (INO) improved oxygenation and reduced the occurrence of
death or extracorporeal membrane oxygenation in term and near-term hypoxic neonates …